Efforts On Prostate And Breast Cancer Tests May Prompt New Drug Development

Phil Febbo, M.D., chief medical officer at Genomic Health, said the move "may reveal potential for guiding treatment selection for prostate cancer patients in the future." The company also recently made a $4 million equity investment to further strengthen its partnership with Biocartis to...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical Processing
Main Author Botta, Mike
Format Trade Publication Article
LanguageEnglish
Published Rockaway Advantage Business Media 06.12.2017
Subjects
Breast cancer
Prostate cancer
Online AccessGet full text

Cover

More Information
Summary:Phil Febbo, M.D., chief medical officer at Genomic Health, said the move "may reveal potential for guiding treatment selection for prostate cancer patients in the future." The company also recently made a $4 million equity investment to further strengthen its partnership with Biocartis to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Score test on the Biocartis Idylla platform that can be performed locally by laboratory partners and in hospitals around the world.
ISSN:1049-9156